Loading…
MCRB
Seres Therapeutics, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 81750R201
$4.02-1.23%Price as of Sep 22, 22:37 UTC · updated once a day, after the close
Key metrics
- Market cap
- $40.38M
- P/E
- —
- Forward P/E
- —
- P/B
- 1.1x
- Dividend yield
- —
- Payout
- —
- EPS
- -$2.42
- ROE
- -66.57%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 0.21
- 52-week high
- $29.98
- 52-week low
- $3.90
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -97.1% over 5Y.
today you would have $25.29▼ -97.5%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 11 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $14.88 | $16.62 | $28.00 | $112.00 | $166.60 | $490.00 | $69.00 | $90.40 | $202.80 | $198.00 | $701.80 | |
| P/E | — | 23.3x | — | — | — | — | — | — | — | — | — |
Fair price, seven ways
Seven formulas applied to what the company reported. None of them predicts a price — each answers what the stock would be worth if its assumption held. The assumption is printed next to every number, because it is the assumption that produces the result.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow
$6.25
Cash flow growing 5.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Operating
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| SNWVSANUWAVE Health, Inc. | $4.68 | 5.8x | 21.8x | — | — | $40.22M |
| NSPRInspireMD, Inc. | $0.85 | — | 1.3x | — | -202.81% | $39.81M |
| ACTUActuate Therapeutics Inc | $1.66 | — | 40.4x | — | — | $39.74M |
| KPTIKaryopharm Therapeutics Inc. | $1.75 |
About the company
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
- 66
- Cambridge, United States
Company description provided by Yahoo Finance.